Our top pick for
Gossamer Bio, Inc is a biotechnology business based in the US. Gossamer Bio shares (GOSS) are listed on the NASDAQ and all prices are listed in US Dollars. Gossamer Bio employs 171 staff and has a market cap (total outstanding shares value) of USD$766.1 million.
|52-week range||USD$7.52 - USD$16.79|
|50-day moving average||USD$10.4445|
|200-day moving average||USD$10.9227|
|Wall St. target price||USD$20.86|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-5.949|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-24.91%|
|Return on equity TTM||-60.56%|
|Market capitalisation||USD$766.1 million|
TTM: trailing 12 months
There are currently 6.4 million Gossamer Bio shares held short by investors – that's known as Gossamer Bio's "short interest". This figure is 14.6% down from 7.5 million last month.
There are a few different ways that this level of interest in shorting Gossamer Bio shares can be evaluated.
Gossamer Bio's "short interest ratio" (SIR) is the quantity of Gossamer Bio shares currently shorted divided by the average quantity of Gossamer Bio shares traded daily (recently around 555459.56896552). Gossamer Bio's SIR currently stands at 11.6. In other words for every 100,000 Gossamer Bio shares traded daily on the market, roughly 11600 shares are currently held short.
However Gossamer Bio's short interest can also be evaluated against the total number of Gossamer Bio shares, or, against the total number of tradable Gossamer Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gossamer Bio's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Gossamer Bio shares in existence, roughly 80 shares are currently held short) or 0.1079% of the tradable shares (for every 100,000 tradable Gossamer Bio shares, roughly 108 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Gossamer Bio.
Find out more about how you can short Gossamer Bio stock.
We're not expecting Gossamer Bio to pay a dividend over the next 12 months.
Over the last 12 months, Gossamer Bio's shares have ranged in value from as little as $7.52 up to $16.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gossamer Bio's is 1.294. This would suggest that Gossamer Bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis both with and without nasal polyps; and in translational Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, selective platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a novel, gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and certain backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.